VKORC1 Polymorphisms, Haplotypes and Haplotype Groups on Warfarin Dose Among African–Americans and European–Americans
- 14 October 2008
- journal article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 9 (10) , 1445-1458
- https://doi.org/10.2217/14622416.9.10.1445
Abstract
Background: Although the influence of VKORC1 and CYP2C9 polymorphisms on warfarin response has been studied, variability in dose explained by CYP2C9 and VKORC1 is lower among African–Americans compared with European–Americans. This has lead investigators to hypothesize that assessment of VKORC1 haplotypes may help capture a greater proportion of the variability in dose for this under-represented group. However, the inadequate representation of African–Americans and the assessment of a few VKORC1 polymorphisms have hindered this effort. Methods: To determine if VKORC1 haplotypes or haplotype groups explain a higher variability in warfarin dose, we comprehensively assessed VKORC1 polymorphisms in 273 African–Americans and 302 European–Americans. The influence of VKORC1 polymorphisms, race-specific haplotypes and haplotype groups on warfarin dose was evaluated in race-stratified multivariable analyses after accounting for CYP2C9 (*2, *3, *5, *6 and *11) and clinical covariates. Results: VKORC1 explained 18% ...Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke (K23NS45598–01)
This publication has 45 references indexed in Scilit:
- Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–AmericansPharmacogenomics, 2008
- CYP4F2 genetic variant alters required warfarin doseBlood, 2008
- Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology & Therapeutics, 2008
- Influence of CYP2C9 and VKORC1 1173C/T Genotype on the Risk of Hemorrhagic Complications in African-American and European-American Patients on WarfarinClinical Pharmacology & Therapeutics, 2007
- Influence of CYP2C9 Genotype on Warfarin Dose Among African–Americans and European–AmericansPersonalized Medicine, 2007
- Evaluation of Genetic Factors for Warfarin Dose PredictionClinical Medicine & Research, 2007
- A worldwide survey of haplotype variation and linkage disequilibrium in the human genomeNature Genetics, 2006
- Racial differences in the prevalence of Factor V Leiden mutation among patients on chronic warfarin therapyBlood Cells, Molecules, and Diseases, 2006
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Evaluating associations of haplotypes with traitsGenetic Epidemiology, 2004